Maria Hafez, MD

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Maria Hafez, MD, explains how hormone receptor status, risk stratification, & other factors influence clinical decisions in early HER2+ breast cancer.